Related Experiment Video
Updated: Jun 8, 2025
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in
Anna Mei1, Kevin P Letscher2, Sai Reddy2
1Department of Biosystems Science and Engineering, ETH Zürich, 4056 Basel, Switzerland; Life Science Zurich Graduate School, ETH Zürich, University of Zurich, 8057 Zürich, Switzerland.
Abstract:
Chimeric antigen receptor (CAR) T cells are a powerful treatment against hematologic cancers. The functional phenotype of a CAR-T cell is influenced by the domains that comprise the synthetic receptor. Typically, the potency of therapeutic CAR-T cell candidates is assessed by preclinical functional assays and mouse models (i.e. human tumor xenografts). However, to date, only a few sets of domains (e.g. CD8, CD28, 41BB) have been extensively tested in preclinical assays and human clinical studies. To characterize the efficiency of a CAR, different assays have been utilized to analyze T cell phenotypes, such as expansion, cytotoxicity, secretome, and persistence. However, each of these previous studies evaluated the importance of an assay differently, resulting in a wide range of functionally diverse CARs. In this review, we highlight recent (high-throughput) methods to analyze CAR domains and demonstrate their impact on inducing T cell phenotypes and activity. We also describe advances in computational methods and their potential for identifying CAR variants with enhanced properties. Finally, we reflect on the need for a standardized scoring system to support the clinical development of next-generation CARs.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for blood cancers. This review explores new methods to analyze CAR domains, aiming to standardize development for next-generation CAR T cells.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cells are a potent immunotherapy for hematologic malignancies.
- The synthetic receptor's domains critically influence CAR T cell function and therapeutic efficacy.
- Current preclinical assessments of CAR T cell potency rely on various assays and mouse models, but limited domain sets have been extensively studied.
Purpose of the Study:
- To review recent high-throughput methods for analyzing CAR domains and their impact on T cell phenotypes and activity.
- To highlight advances in computational approaches for identifying improved CAR variants.
- To emphasize the need for standardized scoring systems to advance next-generation CAR T cell clinical development.
Main Methods:
- Review of recent high-throughput assays for CAR domain characterization.
- Analysis of T cell phenotypes including expansion, cytotoxicity, secretome, and persistence.
- Exploration of computational methods for CAR variant identification.
Main Results:
- Existing studies show diverse CAR T cell functionalities due to varied assay evaluations.
- Recent methods allow for comprehensive analysis of CAR domain effects on T cell activity.
- Computational tools offer potential for discovering CARs with enhanced therapeutic properties.
Conclusions:
- Standardized methods are crucial for evaluating CAR domains and their functional impact.
- Next-generation CAR T cell development requires robust characterization and computational support.
- A unified scoring system will facilitate the clinical translation of novel CAR T cell therapies.
